PLK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Collectively, our findings suggest that combined administration of Aurora kinase A or PLK1 and WEE1 inhibitors could be a promising strategy to enhance apoptosis in TKI-resistant CML cells.